A Prospective Randomized Pilot Study Examining the Role and Effectiveness of Conversion to Sirolimus Versus CNI Reduction in Renal Transplant Patients With Prostate Cancer
This study is designed to support the optimal use of mTOR-inhibitor by providing data for
the safe and effectiveness use with sirolimus. This study will take into account
effectiveness aspects such as malignancy-free survival cancer by reducing the overall
exposure to calcineurin inhibitor.
Interventional
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Malignancy-free survival
Months 3, 9, 15, 21
No
Anil Kapoor, MD
Principal Investigator
McMaster Institute of Urology, McMaster University
Canada: Health Canada
IIS-002-09
NCT00922129
September 2009
January 2011
Name | Location |
---|